Fast-tracking trials into treatments for Parkinson’s
We are at a critical time point in Parkinson’s research. The number of people with Parkinson’s is expected to reach over 12 million by 2040.
Exciting advances mean a number of treatments with the potential to slow Parkinson’s are waiting to be tested. Now we crucially need a way to speed-up their assessment and provide the Parkinson’s community with answers. The current clinical trial process is unable to match the urgent pace required. To accelerate this process, there is a desperate need for smarter, faster, more cost-effective trials. EJS ACT-PD’s goal is to address this challenge, and fast-track trials in to treatments for Parkinson’s.
We want to transform and speed-up the testing of treatments that can slow or stop Parkinson’s
Reveal our answers by hovering your cursor over the questions.
Why is a transformation needed?
What will EJS ACT-PD do differently?
How are EJS ACT-PD addressing this challenge?